Other substances

ACE2-GpA-RBC

A SARS-CoV-2 cellular trap.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

ACE2-GpA-RBC are red blood cells carrying recombinant ACE2 protein and thus serving as SARS-CoV-2 viral traps (SARS-CoV-2 cannot replicate in mature red blood cells, which lack nuclei and some other cellular components). These cells can be continuously produced by BEL-A/CD4-GpA transgenic cell line (Hoffmann et al., 2021).

 

Supporting references

Link Tested on Impact factor Notes Publication date
In vitro characterization of engineered red blood cells as viral traps against HIV-1 and SARS-CoV-2
Spike protein ACE2 Cell-based therapy In vitro 		293T-ACE2 cells; (VSV-G) SARS-CoV-2 Spike pseudovirus 4.53

The cellular traps neutralized SARS-CoV-2 Spike pseudovirus in vitro.

 Mar/10/2021
Export (.csv)